Kageaki Watanabe

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Community Dwelling

Cross Sectional

Top Venues

Translational lung cancer research

Japanese journal of clinical oncology

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Kageaki Watanabe, Keita Sasaki, Ryunosuke Machida, Junichi Shimizu, Yuki Yamane, Motohiro Tamiya, Shin Saito, Yuji Takada, Kiyotaka Yoh, Hiroshige Yoshioka, Haruyasu Murakami, Satoru Kitazono, Yasuhiro Goto, Hidehito Horinouchi, Yuichiro Ohe
High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group). Japanese journal of clinical oncology (2024)
Kazuhito Misawa, Kageaki Watanabe, Masahiro Seike, Yukio Hosomi
Durvalumab plus platinum-etoposide chemotherapy for extensive-stage small cell lung cancer: a retrospective real-world study. Translational lung cancer research 13 (7) (2024)
Shigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata, Kageaki Watanabe, Yukio Hosomi, Hidehito Horinouchi, Yuichiro Ohe, Yoshiro Nakahara, Katsuhiko Naoki, Tetsuhiko Asao, Kazuhisa Takahashi, Sho Saeki, Takuro Sakagami, Kazuhisa Nakashima, Yukari Tsubata, Yu Fujita, Kazuyoshi Kuwano, Megumi Furuta, Jun Sakakibara Konishi, Mayu Ohuchi, Yuichi Ando, Hidenori Mizugaki, Akinobu Hamada
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older. Clinical pharmacology and therapeutics (2024)
Kazuhito Misawa, Kageaki Watanabe, Masahiro Seike, Yukio Hosomi
Durvalumab plus platinum-etoposide chemotherapy for extensive-stage small cell lung cancer: a retrospective real-world study. Translational lung cancer research 13 (7) (2024)
Kageaki Watanabe, Kiyotaka Yoh, Yukio Hosomi, Kazuhiro Usui, Go Naka, Kazuma Kishi, Kohei Uemura, Yasuo Ohashi, Hideo Kunitoh
Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study. BMJ open 12 (1) (2022)